Prevalence of antiretroviral drug genotypic resistance among HIV patients in Cuenca, Spain;Prevalencia de la resistencia genotípica a los fármacos antirretrovirales en pacientes VIH positivos en la provincia de Cuenca

Revista Espanola de Quimioterapia

Volumn 20, Issue 2, 2007, Pages 203-205

  Rodríguez Escudero, Maria José ^a   Prada De Medio, E ^a   Rosa Herranz, C ^a   Martinez Medina M C ^a   Franquelo Gutierrez R ^a  

^a HOSPITAL VIRGEN DE LA LUZ   (Spain)

Author keywords

HIV; Mutations; Resistance

Indexed keywords

ANTIVIRUS AGENT; PROTEINASE; RNA DIRECTED DNA POLYMERASE;

ARTICLE; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PREVALENCE; SPAIN; VIRUS RESISTANCE;

AMINO ACID SUBSTITUTION; ANTI-HIV AGENTS; DRUG RESISTANCE, MULTIPLE, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV PROTEASE; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MALE; MUTATION, MISSENSE; POINT MUTATION; PREVALENCE; RNA, VIRAL; SPAIN;

EID: 34548267701     PISSN: 02143429     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Palella, F.J. Jr. Delaney, K.M., Moorman, A.C. y cols. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338: 853-860.
2. Yerly, S., Kaiser, L., Race, E., Bru, J.P. Clavel, F., Perrin, L. Transmission of antirretroviral drug resistant HIV-1 variants. Lancet 1999; 354: 729-733.
3. Schuurman, R., Nijhuis, M., Van Leeuwen, R. y cols. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in person treated with lamivudine (3TC). J Infect Dis 1995; 171: 1411-1419.
4. Clavel, F. Hance, A.J. HIV drug resistance. N Engl J Med 2004; 350: 1023-1035.
5. De Mendoza, C., Soriano, V., Briones, C. y cols. Emergence of zidovudine associated mutations in patients treated with stavudine. J Acquir Immun Defic Syndr 2000; 23: 279-280.
6. Young, S.D, Britcher, S.F, Tran, L.O. y cols. L-743, 726 (DMP-266): A novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type I reverse transcriptase. Antimicrob Agents Chemother 1995; 39: 2602-2605.
7. Condra, J.H., Holder, D.J., Schleif, W.A. y cols. Genetics correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type I protease inhibitor. J Virol 1996; 70: 8270-8276.
8. Guerrero, A., Cañizares, A., Tomás, S., Velasco, D., Cartelle, M. y grupo de estudio para las resistencias primarias del VIH en España. Prevalencia de resistencia a los fármacos antirretrovirales en pacientes españoles infectados por el VIH y sin tratamiento previo. Enferm Infecc Microbiol Clin 2005; 23: 605-608.
9. Puig, T., Pérez Olmeda, M., Rubio, A. y cols. Prevalence of genotypic resistance to nucleoside analogues and protease inhibitors in Spain. The ERASE-2 study group. AIDS 2000; 14: 727-732.